Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 6—June 2005

Research

Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs

John M. Stelling*†Comments to Author , Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
Author affiliations: *Alliance for the Prudent Use of Antibiotics, Boston, Massachusetts, USA; †Brigham and Women's Hospital, Boston, Massachusetts, USA; ‡The Jones Group, North Liberty, Iowa, USA; §Tufts University, Boston, Massachusetts, USA; ¶AstraZeneca, Macclesfield, Cheshire, United Kingdom

Main Article

Table 2

Odds ratios (OR) and 95% confidence intervals (CI) from multivariate analysis of risk factors for nonsusceptibility in Escherichia coli, 1997–2001*

Drug Factor OR (95% CI) p value
Cefepime (18,239 isolates) Southern Europe 2.23 (1.08–4.69) 0.034
Latin America 4.82 (2.58–9.012) <0.001
North America 0.35 (0.16–0.76) 0.008
Western Pacific 6.39 (1.98–20.56) 0.002
Age group 1.74 (1.09–2.79) 0.021
Intensive care unit 2.84 (1.93–4.17) <0.001
Ceftazidime (19,404 isolates) Southern Europe 2.20 (1.20–4.06) 0.011
Latin America 4.79 (2.83–8.12) <0.001
Age group 1.94 (1.38–2.75) <0.001
Intensive care unit 2.25 (1.69–3.01) <0.001
Ciprofloxacin (19,320 isolates) Northern Europe 1.62 (1.18–2.23) 0.003
Southern Europe 2.99 (2.27–3.93) <0.001
Latin America 3.76 (2.93–4.84) <0.001
North America 0.77 (0.60–0.99) 0.046
Western Pacific 3.07 (1.63–5.76) <0.001
Male 1.46 (1.26–1.68) <0.001
Age group 0.39 (0.29–0.52) <0.001
Year 1.14 (1.07–1.21) <0.001
Gentamicin (18,773 isolates) Latin America 2.44 (1.86–3.20) <0.001
North America 0.74 (0.56–0.97) 0.027
Western Pacific 4.64 (2.66–8.09) <0.001
Male 1.28 (1.09–1.52) 0.004
Age group 1.47 (1.15–1.88) 0.002
Intensive care unit 1.23 (1.01–1.51) 0.042
Piperacillin/tazobactam (19,261 isolates) Southern Europe 2.01 (1.38–2.92) <0.001
Latin America 2.18 (1.60–2.96) <0.001
Western Pacific 2.11 (1.01–4.40) 0.046
North America 0.73 (0.54–0.99) 0.040
Male 1.33 (1.09–1.61) 0.004
Year 0.74 (0.68–0.81) <0.001
Intensive care unit 1.51 (1.24–1.92) <0.001
Tobramycin (18,416 isolates) Southern Europe 1.43 (1.00–2.05) 0.047
Latin America 3.09 (2.31–4.13) <0.001
Western Pacific 3.42 (1.77–6.63) <0.001
North America 0.70 (0.52–0.94) 0.019
Male 1.31 (1.10–1.57) 0.003
Age group 1.66 (1.30–2.13) <0.001
Intensive care unit 1.37 (1.11–1.69) 0.003

*Logistic regression models simultaneously controlled for geographic region, age categories, sex, intensive care unit status, year of specimen, and reporting system. Only significant associations are presented. No significant relationships between nonsusceptibility and reporting system (MYSTIC vs. SENTRY) were found.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO